Trial Profile
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Talimogene laherparepvec (Primary) ; Talimogene laherparepvec (Primary)
- Indications Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 05 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 05 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 21 Sep 2023 Status changed from suspended to active, no longer recruiting.